The in vivo efficacy of peptide-induced WT1-specific CD8+ T cells to reduce tumor burden has been demonstrated in synergic FBL3 and mWT1-C1498 mice tumor models6, 7 and in nude mice inoculated with human tumor cells.8 In the latter study, nude mice engrafted with HLA-24+ lung cancer cells had a prolonged survival and were able to inhibit cancer cell growth following adoptive transfer of HLA-A24/WT1-specific CD8+ T-cell clones. This evidence concerns the gene CD8A and neoplasm.